Found 11 articles for: "Adapalene"
Treatment of Confluent and Reticulated Papillomatosis Using Fixed-Dose Clindamycin phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel
May 2026 | Volume 25 | Issue 5 | Case Reports | 474 | Copyright © May 2026
Introduction: Confluent and reticulated papillomatosis (CARP) is a rare, non-systemic disease usually treated using oral antibiotics.Case Presentation:Read MoreClindamycin Phosphate 1.2%/Adapalene 0.15%/ Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne: A Pooled Analysis by Age
December 2025 | Volume 24 | Issue 12 | Original Article | 1186 | Copyright © December 2025
Background: Acne pathophysiology and presentation may differ between pediatric/adolescent/young adult (9-24 years) and adult (≥25 years) patients. Fixed-dose clindamycin phosp...
Read MoreAssessing Cutibacterium Acnes Susceptibility With Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel Use: Six-Month Analysis
November 2025 | Volume 24 | Issue 11 | Original Article | 1106 | Copyright © November 2025
Background: The only approved triple-combination acne treatment – clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel - demonstrated efficacy/safety ...
Read MoreSafety and Tolerability of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Truncal Acne
August 2025 | Volume 24 | Issue 8 | Original Article | 803 | Copyright © August 2025
Background: Truncal acne is underdiagnosed and undertreated, and it can lead to scarring and postinflammatory hyperpigmentation. However, applying topical treatments to larger sk...
Read MoreClindamycin Phosphate 1.2%/Adapalene 0.15%/ Benzoyl Peroxide 3.1% for Acne: Results From A 6-Month Open-Label Study
May 2025 | Volume 24 | Issue 5 | Original Article | 516 | Copyright © May 2025
Background: Treatment of acne may require many months of treatment before maximal benefits are observed, and acne sequelae (eg, scarring, dyspigmentation) can persist long a...
Read MoreTriple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne in Children and Adolescents
December 2024 | Volume 23 | Issue 12 | Original Article | 1049 | Copyright © December 2024
Background: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose triple-combination approved for acne (indicated in patients ...
Read MoreClindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Participants With Moderate-to-Severe Acne: The Patient Journey
November 2024 | Volume 23 | Issue 11 | Case Reports | 1017 | Copyright © November 2024
Introduction: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose, triple-combination formulation approved for acne treatmen...
Read MoreClindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 Analysis
October 2024 | Volume 23 | Issue 10 | Original Article | 873 | Copyright © October 2024
Background: Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) is the only fixed-dose triple-combination treatment approved for acne. This post hoc analys...
Read MoreSafe Use of Adapalene 0.1 % Gel in a non-Prescription Environment
December 2021 | Volume 20 | Issue 12 | Original Article | 1330 | Copyright © December 2021
Background: Topical retinoids are the mainstay of acne therapy and, until 2016, were only available by prescription. The margin of safety (MOS) of adapalene for potential teratogenic ...
Read MoreTolerability and Efficacy of Clindamycin/Tretinoin versus Adapalene/Benzoyl Peroxide in the Treatment of Acne Vulgaris
March 2021 | Volume 20 | Issue 3 | Original Article | 295 | Copyright © March 2021
Acne vulgaris is the most common dermatological disorder worldwide, causing significant physical and psychological morbidity. Topical combination therapy has shown superior efficacy compared to monoth...
Read MoreRetinoids and Azelaic Acid to Treat Acne and Hyperpigmentation in Skin of Color
April 2013 | Volume 12 | Issue 4 | Original Article | 434 | Copyright © April 2013
In this review, we examine published data reporting the efficacy of pharmaceutical agents to treat associated postinflammatory hyperpigmentation commonly seen in skin of color. Read More
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
